In a report released today, Mark Breidenbach from Oppenheimer assigned a Buy rating to Allogene Therapeutics (ALLO), with a price target of $52.00.
The post Allogene Therapeutics (ALLO) Gets a Buy Rating from Oppenheimer appeared first on Smarter Analyst.
In a report released today, Mark Breidenbach...

https://www.smarteranalyst.com/new-blurbs/allogene-therapeutics-allo-gets-a-buy-rating-from-oppenheimer/

#SmarterAnalyst